Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA: Recall Of BD Alaris Infusion Pump Is High-Risk Class I

Executive Summary

Becton Dickinson’s CareFusion 303 Inc. subsidiary recalled 145,492 of the pumps because there’s a risk that the device’s keypad will lift up and away from the device body if it comes into contact with fluids.

You may also be interested in...



Class I Recall: More Alaris Infusion Pumps Yanked From Market

The US FDA has labeled the recall of nearly 2,500 Alaris Model 8100 infusion pumps as high-risk class I.

Class I Recall Of Alaris Device Is Pump’s Second In 3 Days

Third-party servicer Tenacore LLC recalled the Model 8100 infusion pumps because patients are at risk of receiving incorrect fluid dosage. The recall was designated as class I by the US FDA on 19 April; it’s the pump’s second class I recall in the span of three days.

Q&A: Boston Scientific, BD, Steris Tell How They’re Backing Up Their Workers In ‘The New Normal’

Quality and regulatory officials at the three companies offer tips on supporting the mental health of employees, virtually onboarding new hires, and more in the age of COVID-19.

Topics

UsernamePublicRestriction

Register

MT143801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel